Drug
Prx 102
Prx 102: highest development phase Phase 3, developed by Chiesi Farmaceutici. 1 trial record tracked on RxWires.
- Highest phase
- Phase 3
- Developer
- Chiesi Farmaceutici
Trials
| Drug | Phase | Indication |
|---|---|---|
| PRX-102 (pegunigalsidase alfa) NCT02795676 | Phase 3 | Fabry Disease |
Latest
No recent events.
Follow Prx 102 on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.